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Abstract Cancer is a genetic disease that results from a
variety of genomic alterations. IdentiWcation of some of these
causal genetic events has enabled the development of targeted
therapeutics and spurred eVorts to discover the key genes that
drive cancer formation. Rapidly improving sequencing and
genotyping technology continues to generate increasingly
large datasets that require analytical methods to identify func-
tional alterations that deserve additional investigation. This
review examines statistical and computational approaches for
the identiWcation of functional changes among sets of single-
nucleotide substitutions. Frequency-based methods identify
the most highly mutated genes in large-scale cancer sequenc-
ing eVorts while bioinformatics approaches are eVective for
independent evaluation of both non-synonymous mutations
and polymorphisms. We also review current knowledge and
tools that can be utilized for analysis of alterations in non-pro-
tein-coding genomic sequence.
Introduction
Cancer is a complex genetic disease and understanding the
myriad genetic factors involved in oncogenesis is an impor-
tant step towards prevention and treatment. During the step-
wise process of tumorigenesis, cells acquire a series of
somatic mutations that lead to the excessive cell growth and
eventually lead to the development of cancer. The progres-
sion to cancer can be accelerated when the individual also
carries a germ-line mutation in a cancer susceptibility gene
(Knudson  1971). According to the Cancer Gene Census
(Futreal et al. 2004), the majority of known cancer muta-
tions are somatic mutations, but some germline polymor-
phisms with a connection to cancer have also been
identiWed. IdentiWcation of these mutations and polymor-
phisms can lead to the discovery of the genes that control
cancer development and, therefore, also serve as attractive
therapeutic targets.
The importance of a targeted approach towards cancer
treatment has been emphasized by a number of successful
therapies brought to market in recent years. Novartis’ Glee-
vec is an example of a drug that resulted from the identiW-
cation of a cancer-causing genetic abnormality (Druker
et al. 2001). A chromosomal translocation resulting in the
constitutively active protein tyrosine kinase bcr-abl was
identiWed as the casual event in development of chronic
myelogenous leukemia (Lugo et al. 1990). A small mole-
cule compound was discovered through high-throughput
screening as a potent inhibitor of bcr-abl and it was then
developed into Gleevec, a commercial therapy for inhibit-
ing bcr-abl to block tumor growth while having minimal
eVect upon normal cells. Several other drugs have also been
developed to target speciWc proteins that are commonly
mutated in cancers. For example, Genentech’s Herceptin is
a HER2-speciWc antibody, which is eVective in treating
breast cancers that overexpress the gene HER2, and Astra-
Zeneca’s Iressa was the Wrst of several EGFR inhibitors to
treat carcinomas that have excess EGFR activity (Ciardiello
et al. 2000; Vogel et al. 2002).
Rapid improvements in genomic technologies have
allowed for large-scale genotyping and sequencing of cancer
tissues and normal genomes as well. This inXux of sequence
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data has revealed a vast array of genetic variations present
in cancer, with a large portion of both somatic mutations
and naturally occurring variations in the form of single-
nucleotide substitutions. Among these single-nucleotide
changes, missense mutations in which a single-nucleotide
change within a gene results in an amino acid substitution
in the protein product are the most investigated (Ding et al.
2008; Forbes et al. 2008; Greenman et al. 2007; Jones et al.
2008; TCGA 2008; Parsons et al. 2008; Sjoblom et al.
2006; Wood et al. 2007). The primary question facing the
interpretation of this wealth of data is the delineation of
functional mutations from those that are simply the result of
the genetic instability inherent in cancer genomes.
The most common ways of analyzing missense muta-
tions are focused on two distinct but related goals. In the
case of recently published large-scale sequencing eVorts,
the analysis is gene-centric and attempts to identify highly
mutated genes that are, therefore, likely to be important in
the development of a speciWc cancer (Ding et al. 2008;
Greenman et al. 2007; Jones et al. 2008; TCGA 2008; Par-
sons et al. 2008; Sjoblom et al. 2006; Wood et al. 2007).
The premise behind this frequency-based approach is that
genes that are mutated signiWcantly more often than would
be expected by chance probably function to favor tumor
growth when mutated. This methodology requires a large
dataset to provide suYcient statistical power and its
strength lies in the identiWcation of important genes in the
condition of interest. Complementary to this approach is a
mutation-centric view that removes a given mutation from
the disease context in which it was observed and attempts
to predict its functionality based solely on the substitution
itself. These methods have the beneWt of being able to
potentially identify the actual causal mutation, as opposed
to just the causal gene. IdentiWcation of speciWc functional
mutations could give additional insight into the biological
mechanisms of the disease.
Although the majority of large-scale sequencing eVorts
to date have focused on protein-coding regions, next gener-
ation sequencing technologies are beginning to allow for
whole-genome sequencing of individual samples (Ley et al.
2008; Wheeler et al. 2008). This will bring in a wealth of
information on mutations occurring in non-genic genomic
regions, which will in turn require diVerent analysis tech-
niques. Single-nucleotide polymorphism (SNP) analysis
has shown that alterations in non-coding sequences can
have signiWcant functional eVects and contributions
towards disease (Chorley et al. 2008; Srebrow and Kor-
nblihtt  2006), and so making full use of whole-genome
sequencing data will require analysis of mutations found
outside of genes. The tools for predicting the functionality
of a non-coding mutation are limited, but there exist a num-
ber of methods and databases that attempt to map the vari-
ous non-coding functional regions to the genome through
sequence analysis (Cartegni et al. 2003; Conde et al. 2006;
Enright et al. 2003; Freimuth et al. 2005; GriYths-Jones
et al. 2008; Hallikas et al. 2006; Kim et al. 2008; Lambert
et al.  2004; Matys et al. 2003; Palin et al. 2006; Pono-
marenko et al. 2002, 2003; Riva and Kohane 2002; Sande-
lin et al. 2004; Tabaska and Zhang 1999; Thierry-Mieg and
Thierry-Mieg 2006; Wang 2008). These tools model spe-
ciWc sequence elements such as transcription factor-binding
sites based on the experimentally veriWed regions and pro-
vide the most eVective means of large-scale prediction of
where functional sites lie. They can also help in functional
prediction by Wrst identifying mutations that lie in func-
tional elements, and if so, which ones may perturb the func-
tionality of that element. Most such tools give a
quantitative measure of how likely a given sequence is to
be a functional element of interest (e.g. transcription factor-
binding site), and so simply examining the diVerence in
scores between a mutated sequence and its original
sequence can give an idea of the functionality of the muta-
tion.
Distinct from the study of somatic mutations in cancer is
the investigation of naturally occurring human germline
mutations that could contribute to the risk of cancer and
other genetic diseases. A large number of SNPs have been
identiWed, but functional information is still sparse (Sherry
et al.  2001). Large-scale systematic genotyping projects
(Frazer et al. 2007) have employed high-throughput geno-
typing technologies that enable investigations into associa-
tions between variation and disease risk. Genome-wide
association studies (GWAS) have discovered SNPs that
contribute to the risk of cancer development, but many of
the identiWed risk alleles require additional analysis to vali-
date and understand (Amos et al. 2008; Broderick et al.
2007; Easton et al. 2007; Eeles et al. 2008; Gold et al.
2008; Gudmundsson et al. 2007; Hunter et al. 2007; Kings-
more et al. 2008; Tenesa et al. 2008; Thomas et al. 2008;
Tomlinson et al. 2008; Zanke et al. 2007). SNPs are distrib-
uted throughout the human genome in both coding and non-
coding regions, but many methods used for analyzing
mutations are equally valuable for evaluating the potential
functionality of SNPs, which could be a valuable step
towards the interpretation and utilization of GWAS data.
This review focuses on the analysis of single-nucleotide
substitutions in the context of cancer, with a particular spot-
light on recent large-scale cancer genome sequencing pro-
jects. We examine the methods by which cancer sequencing
eVorts can leverage their data to identify disease-driving
genes and provide an overview of amino acid-change-based
bioinformatics analysis methods, many of which are also
applicable to non-cancer inherited diseases (Karchin 2009;
Mooney 2005; Ng and HenikoV 2006; Steward et al. 2003).
We also review the current knowledge of functional muta-
tions that act in ways other than alteration of proteinHum Genet (2009) 126:481–498 483
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sequence, such as mutations that alter gene expression or
splicing.
Mutation frequency-based analysis
Several large-scale cancer genome exon re-sequencing pro-
jects have recently been published by four publicly funded
consortiums including groups at John Hopkins University
(JHU) (Jones et al. 2008; Parsons et al. 2008; Sjoblom et al.
2006; Wood et al. 2007), Sanger Institute (Greenman et al.
2007), the Cancer Genome Atlas (TCGA 2008), and the
Tumor Sequencing Project (TSP) (Ding et al. 2008)
(Table 1). The JHU group focused on sequencing nearly the
complete human transcriptome with a limited number of
samples (11–24 samples in each cancer type), whereas the
other groups sequenced a smaller number of candidate
genes and, therefore, could aVord to cover a larger number
of samples in a single cancer type (as high as 188 lung ade-
nocarcinoma samples in the case of the TSP study).
Although the Wrst strategy allows for the detection of novel
cancer genes due to the larger search space, the latter strat-
egy enables a broader survey of possible mutations in genes
that are already known to be involved in cancer.
It has been estimated that most of the observed cancer
mutations are functionally neutral and are, thus, often
referred to as passenger mutations, while a smaller set of
driver mutations will actually confer growth advantages to
tumors (Greenman et al. 2007; Sjoblom et al. 2006). Driver
mutations increase the Wtness of cells that they reside in and
are assumed to be under positive selection during the multi-
stage neoplastic progression. This selection should result in
driver mutations occurring more frequently in tumor sam-
ples; hence, the most common approach for identifying
driver mutations is based on calculating mutation frequen-
cies with the assumption that a higher prevalence implies
functionality. This method of frequency-based analysis typi-
cally requires an estimation of the non-synonymous back-
ground mutation rate (nsBMR) followed by calculation of
the statistical likelihood of observing a certain number of
mutations based on the nsBMR. For example, a gene har-
boring a signiWcantly greater number of mutations than
expected by chance would be considered a driver, since it is
likely that mutations in that gene are selected for during
oncogenesis. In the following sections, we will discuss how
mutation data were analyzed in the recently published can-
cer genome studies with regard to the above-referenced
steps.
It is crucial to determine a valid nsBMR, which, if
underestimated, would overstate the signiWcance of the
observed mutations. The nsBMR can be estimated empiri-
cally from presumed passenger mutations as shown in the
studies conducted by Jones et al. (2008); Parsons et al.
(2008). These studies estimated that the nsBMR from the
set of genes remaining after the most highly mutated previ-
ously known driver genes were removed from the dataset.
More commonly, nsBMR is indirectly estimated as the
product of the mutation rate of synonymous mutations and
the expected ratio of the number of passenger non-synony-
mous mutations to the number of synonymous mutations
(NS/S). With rare exceptions, a synonymous mutation is
not likely to change the function of the protein and is, there-
fore, usually considered functionally neutral and not subject
to selective pressure (Greenman et al. 2006). The passenger
NS/S ratio is obtained by dividing the total number of pos-
sible non-synonymous changes by the total number of pos-
sible synonymous changes within the sequenced
nucleotides (Ding et al. 2008; TCGA 2008; Wood et al.
2007). This ratio, ranging from 2 to 3, may result in an
overestimation of the nsBMR because some of the possible
non-synonymous mutations may be detrimental to the
growth of the tumors and are, thus, under negative selec-
tion. A diVerent approach is to use the observed NS/S in
human population SNPs, approximately 1 (Jones et al.
2008; Parsons et al. 2008; Wood et al. 2007), which may
result in an underestimation due to a greater selective pres-
sure on germline mutations. Because these approaches,
respectively, delineate an upper bound and lower bound for
the NS/S ratio, the average of the two values is used by the
Jones et al. (2008); Parsons et al. (2008) studies.
Estimation of a background mutation rate can be signiW-
cantly aVected by mutation rate heterogeneity across diVer-
ent DNA contexts. For example, CpG dinucleotides have a
much higher mutation rate (up to 6.44-fold higher than the
overall mutation frequency in one colorectal dataset (Sjob-
lom et al. 2006)) compared with other DNA contexts.
Owing to this context-dependence, it can be beneWcial to
partition mutations into multiple types to account for such
variations (Ding et al. 2008; Greenman et al. 2007; Jones
et al. 2008; TCGA 2008; Parsons et al. 2008; Sjoblom et al.
2006; Stephens et al. 2005; Wood et al. 2007). The relative
mutation rates of the diVerent DNA contexts are usually
measured directly using mutations that are presumably non-
functional, such as synonymous mutations or mutations
observed on the least frequently mutated genes (TCGA
2008). DNA context groups can be deWned either based on
prior knowledge, such as the high mutation rate at CpG
dinucleotides, or using data-driven methods, which may
better capture the heterogeneity of the mutation rates across
diVerent nucleotide contexts (Ding et al. 2008; Jones et al.
2008; TCGA 2008; Parsons et al. 2008; Sjoblom et al.
2006; Wood et al. 2007). In a recent study of lung carci-
noma, Ding et al. 2008 partitioned all of the observed muta-
tions into 192 categories with consideration of all 12
possible mutation changes within 16 possible Xanking
dinucleotides (5 and 3). Observed mutation rates for each484 Hum Genet (2009) 126:481–498
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category were calculated and low frequency categories
were then collapsed if they did not show statistically dis-
tinct mutation rates (P < 0.05, Fisher exact test). This pro-
cess resulted in 18 distinct categories. Recently, the JHU
group and the TCGA group each published a glioblastoma
study in which they reported two quite diVerent background
mutation rates: 0.38–1.02 (estimated lower and upper
bounds) and 3.70 § 0.57, respectively (TCGA 2008;
Parsons et al. 2008). This discrepancy is likely due to the
heterogeneity between the two sample populations and
gene sets, as evidenced by the diVerence in the observed
synonymous mutation rate (0.37 and 1.29). Further study
might suggest that the most eVective method is to use gene-
speciWc nsBMRs to reduce the disparities between separate
studies, but a large amount of data is necessary to use this
method eVectively.
Several studies identify novel putative cancer genes
using statistical methods, some of which have stirred con-
troversies (Forrest and Cavet 2007; Getz et al. 2007; Rubin
and Green 2007). Most of these studies applied the one-
tailed binomial test to identify signiWcantly mutated genes,
followed by a false discovery rate procedure to control for
multiple testing (Benjamini and Hochberg 1995). As men-
tioned above, a single Wxed background mutation rate was
used in the simplest version while a more complex
approach took into account the DNA context of each muta-
tion to adjust for the heterogeneity of mutation rates under
diVerent DNA contexts. As shown in TCGAs analysis, the
context-speciWc method is more sensitive when a smaller
set of samples is analyzed (TCGA 2008). It is also worth
noting that a custom method was used by the JHU group to
incorporate their unique two-stage experimental design
(discovery and validation screens) into the analysis (Jones
et al. 2008; Parsons et al. 2008; Wood et al. 2007). Greenman
et al. (2007) used a diVerent strategy of directly modeling
the NS/S ratio based on the rationale that if non-synony-
mous mutations yield amino acid changes with a selective
advantage, a higher ratio of NS/S may be observed. There-
fore, the signiWcance of the results can be measured as a
function of the degree of deviation from the expected 2:1
ratio, which had been used in several early studies (Bardelli
et al. 2003; Samuels et al. 2004; Wang et al. 2004). With
this model, the selective pressure can be estimated for vari-
ous gene sets via maximum likelihood by considering the
deviation from the expected ratio of non-synonymous to
synonymous mutations. The selection pressure can be cal-
culated on diVerent levels, from a single gene to the whole
mutation dataset, from which candidate driver genes can be
predicted and the number of driver mutations can be
estimated.
Another factor that could greatly aVect the result of a fre-
quency-based study is the sample size present in the study.
A wide range of sample sizes has been processed in the
published large-scale sequencing eVorts, ranging from 11 in
breast and colon cancers to about 200 in lung cancer. The
authors of the TCGA study have examined the eVects of
sample size by randomly selecting subsets of the original
72 samples (TCGA 2008). They found that with as few as
48 samples, all eight of the cancer genes that were identi-
Wed in their complete set of 72 samples could still be dis-
covered. When the sample size was further reduced, only a
fraction of the eight genes could still be identiWed as signiW-
cant.
Somatic point mutations may account for only a fraction
of the genetic alterations required for tumorigenesis. Inte-
gration with other genomic data would greatly enhance the
possibility of identifying genes and biological pathways
involved in tumor development. In the glioblastoma study,
Parsons et al. (2008) integrated mutation analysis with
genomic copy number analysis and identiWed three major
signaling pathways with critical genes mutated in a major-
ity of the studied tumors. They also found a mutually exclu-
sive pattern for the alterations within each pathway. The
same pattern was also reported in TCGAs glioblastoma
paper (TCGA 2008). Ding et al. (2008) found that muta-
tions in known tumor suppressor genes such as PTEN, APC
and TP53 were correlated with copy number loss and muta-
tions in proto-oncogenes, such as EGFR, HCK, KRAS and
EPHB1. Therefore, an integrative approach to analyze all
types of genetic alterations in a pathway context could pro-
vide greater insight into the genetic mechanisms of cancer
development.
Many of the somatic mutations identiWed in the recent
cancer exon re-sequencing studies are novel and rare muta-
tions, often observed in only a single sample. This implies
that a large number of samples are required to establish the
statistical signiWcance of potential cancer driver genes. The
rapid development of sequencing technology will eventu-
ally allow us to expand beyond the current focus on coding
regions to the whole human genome and therefore make it
possible to identify all of the genetic alterations underlying
the individual cancers. In the meantime, it also presents an
even bigger statistical challenge since many more muta-
tions need to be analyzed. Despite these challenges, the cur-
rent large-scale cancer studies have successfully identiWed
many novel cancer genes and provide more insight into the
complex genetic basis of cancer (Table 1) .
Bioinformatics analysis of amino acid substitutions
The frequency-based approaches reviewed above are con-
tingent upon either an assumption of a background muta-
tion rate or the availability of a large number of mutations
in the dataset to calculate an empirical background muta-
tion rate for the sample of interest. Furthermore, theseHum Genet (2009) 126:481–498 485
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methods cannot be used for independently evaluating the
potential function of an individual mutation. Because many
genes are infrequently mutated and large disease-speciWc
datasets are often not available, other approaches may be
more suitable for identiWcation of functional mutations on
an individual gene basis. A set of methods for predicting
functions of speciWc amino acid substitution can Wll this
niche (Table 2). These methods look at the actual amino
acid change occurring in missense mutations and can be
used for the analysis of mutations on a case-by-case basis.
Such methods have also been eVective in the study of natu-
ral human genetic variation. Bioinformatics methods can
help prioritize which of the greater than 60,000 estimated
non-synonymous single SNPs (Livingston et al. 2004) in
the human population are likely to have a function impact
and warrant additional investigation. Furthermore, the
ability of such methods to evaluate the functional impact of
individual changes makes them useful for directing muta-
genesis eVorts, so that mutations that are most likely to pro-
duce a phenotype can be examined Wrst (HenikoV and
Comai 2003). We will review general features of substitu-
tion-based methods and focus speciWcally on their applica-
tion towards cancer mutation research.
Amino acid-change-based prediction methods are pri-
marily based on an observation that functional mutations
appear to be distributed in a non-random manner across
protein sequences and structures (Miller and Kumar 2001;
Sunyaev et al. 2000; Wang and Moult 2001). Based only on
sequence analysis, Miller and Kumar (2001) observed that
disease-associated mutations in seven genes were particu-
larly concentrated in conserved amino acid positions. This
observation is consistent with the notion that conserved resi-
dues are more likely to be functional, since the conversation
at that position is likely due to purifying selection through-
out evolution. By adding structural data to their analysis,
Sunyaev et al. (2000) found that »70% of disease-related
mutations they studied were located in structural sites more
likely to be functionally important, such as active sites,
interaction sites, or positions buried within the protein and
inaccessible to solvent. In a similar manner, Wang and
Moult (2001) modeled the eVects of disease-associated
SNPs on protein stability and found that 83% of such
substitutions were found to aVect protein stability.
Given the observations concerning disease-related muta-
tions, algorithms that predict the functionality of amino
acid substitutions do so based on sequence information,
structure information, or a combination of the two. In
sequence-based methods, a substitution will be evaluated
based on its sequence context. The widely used SIFT algo-
rithm (Sorting Intolerant From Tolerant) employs a multi-
ple sequence alignment of homologous proteins to identify
conserved regions in the protein of interest, each possible
substitution can then be scored according to the conserva-
tion observed at each position (Ng and HenikoV  2001).
Similarly, CliVord et al. describe a tool that takes advantage
of known Pfam protein motifs to identify conserved regions
in protein domains (CliVord et al. 2004; Finn et al. 2006).
Jiang et al. (2007) developed a method consisting of 20
modules, each of which was optimized using a subset of
sequence features speciWc to a particular starting residue.
This method was shown to outperform other general meth-
ods such as SIFT. More recently, Hon et al. (2009) exam-
ined mutations within signal peptide regions and used
outputs from the SignalP program to identify mutations that
could aVect signal peptide function. The authors found that
combining SIFT with speciWc signal peptide information
could accurately identify functional mutations within signal
peptides. This context-speciWc approach was also adopted
by Radivojac et al. who developed a model using the output
of phosphorylation-site predictor DisPhos to assess the
probability of losing or gaining phosphorylation sites due to
mutation. The application of this model onto a cancer
genome dataset (Greenman et al. 2007) revealed that cancer
somatic mutations are enriched for mutations that aVect
phosphorylation sites (Radivojac et al. 2008).
Structure-based amino acid substitution prediction meth-
ods rely on an ability to map mutations of interest to a
structure. In these methods, the Wrst step is to Wnd a suitable
structure for the protein of interest and then identify the
possible structural eVects that the given amino acid substi-
tution may have. For example, changes that aVect solvent
accessibility or at sites of protein–protein interactions are
more likely to be functional. PolyPhen is a rule-based sys-
tem that uses structural information and annotation data to
identify functionally important sites to predict the potential
function of a substitution (Sunyaev et al. 2001).
Just as frequency-based methods are heavily dependent
upon available mutation information, substitution-based
algorithms are limited by available sequence and structure
information. For instance, three-dimensional structures are
only available for a small fraction of all proteins, and not in
all functional conformations. In this case, applying a struc-
ture-based algorithm to a protein with only limited struc-
tural information would not produce accurate results
(Chasman and Adams 2001; Yue et al. 2005; Yue and
Moult  2006). In an analogous manner, sequence-based
methods can be limited by the number of available
sequences homologous to the protein of interest. Predic-
tions will be less accurate in cases where an inadequate
number of sequences are used to identify conserved resi-
dues. Even with a large set of homologous sequences, how-
ever, it has been shown that many disease-causing
mutations are in positions that are not highly conserved
across species and could therefore be subject to less accu-
rate analysis by sequence-based methods (Torkamani and
Schork 2007b).Hum Genet (2009) 126:481–498 487
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The previously mentioned methods can be generally
applied towards analysis of amino acid substitutions. How-
ever, cancer driver mutations have particular characteristics
that Kaminker et al. (2007a) exploited with the CanPredict
algorithm to distinguish cancer mutations from others
based on annotation and sequence features. CanPredict
applied speciWc knowledge of cancer mutations to distin-
guish them from other disease mutations in a manner simi-
lar to how disease mutations can be distinguished from
non-functional mutations. In particular, CanPredict incor-
porates sequence-based predictions from two previously
mentioned methods (SIFT and Pfam-based LogR.E-value)
(CliVord et al. 2004; Ng and HenikoV  2001) as well as
annotation information from Gene Ontology (Ashburner
et al. 2000) into a random forest classiWer (Breiman 2001).
This classiWer quantiWes the diVerences in these features
between cancer-related mutations and others and is then
able to provide a call for whether or not a given mutation is
likely to be a causal mutation in cancer.
Subsequently, Torkamani and Schork (2008) reported an
SVM-based classiWer to distinguish cancer driver muta-
tions. A collection of sequence and structure features were
used in their model, including sequence conservation mea-
sured with the SubPSEC score (Thomas et al. 2003; Tho-
mas and Kejariwal 2004), the wild-type and mutant amino
acid identity (Torkamani and Schork 2007b), changes in
Wve amino acid metrics (Atchley et al. 2005), changes in
hydropathy, water/octanol partition energy, hydrophobic-
ity, polarity, charge and volume, protein domain informa-
tion, protein secondary structure, amino acid solvent
accessibility and structure Xexibility predicted by Wiggle
(Gu et al. 2006). Only mutations within protein kinase fam-
ilies are analyzed in this study, which allows the incorpora-
tion of two protein kinase-speciWc features into the model.
The subgroup annotation of the speciWc protein kinase was
used as the Wrst feature since the distributions of disease
and non-disease mutations within diVerent protein kinase
groups are signiWcantly diVerent. The second feature is the
subdomain predictor of whether a given mutation falls
within the N-terminal or the C-terminal lobe, since disease
mutations have a tendency to cluster within the C-terminal
lobe rather than the N-terminal lobe. The authors showed
that this context-speciWc method outperforms CanPredict
on the kinase mutations. In a diVerent study, Torkamani
et al. reported that their method is also superior to other
popular methods (SIFT, Polyphen, Pmut, and SNPs3D)
applied to germline variants within protein kinases (Torka-
mani and Schork 2007a). They attributed much of their suc-
cess to the context-speciWc training data, where speciWc
protein kinase features such as the group membership can
be used.
The protein sequence and structure-based analysis have
also been applied in the recent large-scale cancer genome
projects in order to help prioritize genes and somatic muta-
tions for further validation (Ding et al. 2008; Jones et al.
2008; TCGA 2008; Parsons et al. 2008; Wood et al. 2007).
Ding et al. (2008) used SIFT and PolyPhen to evaluate the
potential impact on protein function for 811 missense muta-
tions. SIFT predicted 430 missense mutations as deleterious
while PolyPhen predicted 438 mutations as probably/possi-
bly damaging. Taken together, 579 mutations were identi-
Wed as likely to aVect protein function. Wood et al. (2007)
used two sequence analysis tools, SIFT and logR.E to prior-
itize mutations for further analysis. After projecting muta-
tions onto protein structures, they observed that some
somatic mutations showed clustering of mutations around
active sites of proteins or near an interface residue. In the
glioblastoma and pancreatic cancer studies by the same
research group, a machine learning classiWer using a ran-
dom forest algorithm, LSMUT, was developed to predict
the functional impact of the non-synonymous mutations
(Jones et al. 2008; Parsons et al. 2008). Fifty-eight features
based on the sequence and structural information of amino
acids involved in the alterations were used as the predictive
features for the classiWer. The classiWer was trained on
common SNPs as the negative dataset (common SNPs are
assumed to be tolerated and therefore not disease-causing)
and cancer mutations in the COSMIC database as the posi-
tive dataset. The distribution of LSMUT scores of the mis-
sense mutations in the top-ranked CAN genes is
signiWcantly diVerent from the scores in a set of randomly
generated mutations. Approximately 15 and 17.3% of the
missense mutations that can be predicted by the classiWer
were predicted to aVect protein function in the glioblastoma
and pancreatic cancer datasets, respectively. Furthermore,
using protein structure information, they discovered that
over 10% mutations (35 in glioblastoma and 55 in pancre-
atic cancer) are located close to a domain interface or sub-
strate-binding site and thus are likely to aVect protein
functions.
The frequency-based analysis approaches and amino
acid substitution prediction methods have been compared
in a few papers. The two methods were found to produce
the results that correlate well with each other. Indeed, muta-
tions in genes that have a high CaMP score tend to be also
classiWed as cancer-associated using CanPredict (Hon et al.
2008). Similarly, functional scores computed by combining
the predictions of PolyPhen, PMut, SIFT and SNPs3D cor-
related with the odd ratios identiWed in association studies
(Zhu et al. 2008). More importantly, these two approaches
may work together in a complementary nature. For exam-
ple, CanPredict can capture the functional eVect of known
driver mutation BRAF V600E (Kaminker et al. 2007a),
which was missed by frequency analysis due to the lack of
enough samples (Sjoblom et al. 2006). Many prediction
tools have been developed in recent years to identify theHum Genet (2009) 126:481–498 489
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potential functionality of amino acid substitutions
(Table 2). However, these tools often produce inconsistent
results, making interpretation of the individual results more
diYcult. Chan et al. (2007) show that when the predictions
of four diVerent methods are in agreement the prediction
accuracy is signiWcantly improved. Others have proposed a
metaserver to enable end users to more easily access con-
sensus prediction results from diVerent prediction servers
(Karchin 2009; Ng and HenikoV 2006). With high-through-
put, next generation sequencing technology becoming
increasingly reliable and aVordable, future cancer genome
studies are likely to be sequencing the entire genome in
large collections of cancer samples. Therefore, the power of
frequency-based analysis will be increased accordingly. In
the meantime, the amino acid-based bioinformatics analysis
will become even more critical as more rare mutations are
identiWed.
It is well known that there are some recurrent cancer
“hotspot” mutations that can be observed in many samples,
for example BRAF V600E is reported in over 4,000 sam-
ples according to COSMIC database. Moreover, cancer
mutations are also found to be located at the locations that
are analogous to other known mutations. For example, the
T790M mutation in EGFR occurs at the same residue in the
kinase domain as other known mutations in BCR-ABL,
PDGFRA and KIT (Kobayashi et al. 2005). Marks et al.
(2007) reported a novel mutation in the kinase domain of
FGFR4, which is located at an analogous location to a
known cancer mutation in ERBB2, which lead to the devel-
opment of the “Mutagrator” web site (http://cbio.
mskcc.org/mutagrator/) to capture a few other analogous
mutation clusters in the protein kinase domain. Wood et al.
also discovered a number of cancer mutations that occurred
at locations identical to those of genes involved in human
germline diseases. Based on this concept, one may develop
a mutation cluster analysis tool to identify the analogous
mutation clusters between cancer and germline disease
mutations. Such a tool would be a valuable in addition to
the existing bioinformatics tools for identifying functional
mutations.
Analysis and signiWcance of non-coding functional 
variants
We have thus far focused exclusively on reviewing the
analysis of non-synonymous coding mutations, but there
are several ways in which single-nucleotide mutations may
give rise to abnormal function and therefore potentially
lead to a disease phenotype. In addition to amino acid sub-
stitutions, single-nucleotide changes may also result in
irregular gene expression through modiWcation of regions
of the genome important for regulation of transcription,
such as transcription factor-binding sites (Knight 2005;
Pastinen and Hudson 2004). In addition, most human genes
require post-transcriptional processing before resulting in a
mature mRNA, so modiWcations in splice sites or polyade-
nylation may also lead to altered protein function. Finally,
mutations in any of the many regulatory RNAs that the
genome encodes could result in an undesired phenotype
through abnormal regulation of gene expression. Here, we
will review experimental evidence demonstrating that
mutations in these non-translated regions can have an eVect
on human health and give an overview of methods and
resources that can be applied towards large-scale functional
characterization of these non-coding features.
Regulatory SNPs
Gene expression is a tightly regulated cellular process and
so mutations that aVect gene expression can have a pro-
found phenotypic eVect or dramatically increase disease
risk. Depending on the gene in question, variations that
increase or decrease the expression of a gene can both have
deleterious eVects. One example of overexpression increas-
ing disease susceptibility is in the MDM2 gene where a sin-
gle nucleotide change known as SNP309 alters
transcription factor binding (Bond et al. 2004). Individuals
with a T=>G mutation show a substantially increased risk
for developing colorectal cancer. MDM2 acts as an inhibi-
tor of the p53 tumor suppressor pathway, and the evidence
suggests that a guanine at SNP309 results in overexpression
of MDM2, which in turn leads to increased suppression of
the p53 pathway and increased risk of cancer development
(Bond et al. 2005; Bond and Levine 2007). Another regula-
tory SNP of interest to cancer researchers is the 938C/A
polymorphism present in the promoter region of the BCL-2
anti-apoptosis gene. The alanine variant of this polymor-
phism is thought to reduce the expression of BCL-2 relative
to wild-type expression, which would in turn provide low
risk of cancer development. In fact, studies have shown that
BCL-2 938A is associated with decreased risk in prostate
cancer and squamous cell carcinoma (Chen et al. 2007;
Kidd et al. 2006). However, an additional study with a
small patient set could not Wnd association between protein
levels of BCL-2 and any laboratory or clinical features of
chronic lymphocytic leukemia (Majid et al. 2008). In one
further example that is distinct from the MDM2 and BCL-2
SNPs above, rs6983267 is an SNP in an intergenic region
of 8q24 which is hundreds of kilobases away from the near-
est functional gene. Multiple independent studies have
shown that the guanine allele at this position is associated
with several cancers, most prominently colorectal cancer
(Haiman et al. 2007; Tomlinson et al. 2007; Tuupanen et al.
2008; Zanke et al. 2007). In this case, it is unclear whether
rs6983267 is functional by itself through disruption of a490 Hum Genet (2009) 126:481–498
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long-range enhancer element or if it is tightly linked to
another functional variant.
In a manner analogous to GWAS to discover SNPs cor-
related with complex traits, several studies have attempted
large-scale eVorts to associate SNPs with gene expression
phenotypes (Cheung et al. 2003; Cheung and Spielman
2002; Cheung et al. 2005; Morley et al. 2004; Spielman
et al. 2007). Rather than thinking of a disease condition as a
phenotype, these studies utilize speciWc gene expression
levels as the phenotype of interest and they discover a large
number of genetic markers that are tightly associated with
expression phenotypes. The results of these studies eVec-
tively comprise a list of candidate regulatory SNPs. Since
with more traditional GWAS, it is not apparent without
additional experimentation which of the associated SNPs
are actually causal, as opposed to simply correlated. Even
with the identiWcation of many associated SNPs, it is likely
that experiments are needed to Wlter for the genotypes that
directly contribute to the gene expression phenotype. For
example, although association of rs6983267 to cancer has
been found, it would require detailed experimentation to
resolve whether or not the SNP is causal, and if so whether
it is tissue-speciWc. Such experiments are often performed
with reporter assays where promoters containing the candi-
date alleles are used to drive expression of a reporter gene
such as Luciferase (Cheung et al. 2005; Ogasawara et al.
2008), so that allele-speciWc expression can be quantiWed.
Even so, however, identifying mutations that alter expres-
sion of key genes may still not result in discovering the
causal factor in disease since it would have to be shown that
the modiWed expression results in the observed phenotype.
In cases such as rs6983267, the causal factor ends up being
extremely diYcult to detect since it is not near any gene and
so even if it is aVecting expression, identiWcation of the
genes that it is directly aVecting can be a diYcult problem.
In one case where signiWcant experimental evidence has
provided a strong theory for a regulatory SNP being
responsible for driving disease, De Gobbi et al. (2006)
characterized an SNP associated with the blood disorder -
thalassemia. This SNP does not alter protein function
directly, but instead it lies in an intergenic region within the
-globin gene cluster, which has been associated with -
thalassemia onset. The disease-associated variant is in fact
a gain-of-function mutation that results in a new transcrip-
tional promoter for the GATA-1 transcription factor being
created in the midst of the gene cluster. Activation of tran-
scription at this new promoter appears to result in sup-
pressed expression of downstream -globin genes, which
leads to -thalassemia (De Gobbi et al. 2006).
A number of computational tools have been developed
to help with the analysis of SNPs (Mooney 2005), and
many of them have speciWc features towards the identiWca-
tion of regulatory SNPs. A recent review on methods for
annotating SNPs provides a detailed description of many of
these resources (Karchin 2009). With regards to functional
analysis of regulatory SNPs, the general paradigm is to uti-
lize existing databases of transcription factor-binding sites,
such as TRANSFAC and JASPAR to identify SNPs that
may map to important regulatory regions (Matys et al.
2003; Sandelin et al. 2004). Transcription factor-binding
site mapping is primarily accomplished through identiWca-
tion of genomic elements that match known sequence
motifs or positional weight matrices, so there can be a
quantitative measure of how close a given sequence is to
the canonical binding site. A method of predicting whether
or not a nucleotide change will have an eVect on gene
expression could be to score both the wild-type and the var-
iant sequences for transcription factor binding and look for
diVerences (GuhaThakurta et al. 2006). Any perturbation of
a binding site could result in a functional eVect, since
reducing transcription factor binding will cause deregula-
tion of the target gene, whereas introducing a new site
could cause undesired transcription (De Gobbi et al. 2006).
For example, JASPAR sequence analysis of two breast-
cancer susceptibility SNPs (rs7895676 and rs2981578) in
the FGFR2 locus shows that they are likely to aVect tran-
scription factor binding. In each case, JASPAR scores one
allele with a high similarity to the known transcription fac-
tor-binding site whereas the other receives a score below
the default 0.80 relative proWle score threshold. Detailed
experimental evidence conWrms that the minor allele C in
rs7895676 disrupts binding of C/EBP while the minor
allele G in rs2981578 increases binding aYnity of Runx2
(Meyer et al. 2008).
Post-transcriptional processing SNPs
Single-nucleotide mutations can aVect the cell in ways even
beyond amino acid substitution and transcriptional regula-
tion. There are several cases of SNPs aVecting protein func-
tion through alterations in splicing rather than aVecting
protein structure through amino acid substitution (Pagani
and Baralle 2004; Srebrow and Kornblihtt 2006). Further-
more, gene expression can be regulated through means such
as micro RNAs (miRNAs) or polyadenylation rather than
through genomic regulatory regions. These factors can also
be inXuenced through mutation and result in abnormal
phenotypes.
Splicing mechanisms in humans are relatively well
known and with the genome tools available today, it has
become possible to systematically identify genomic sites
important in splicing, which in turn allows the identiWcation
of variants that may aVect splicing. Several large-scale
eVorts have attempted to identify SNPs that may have an
eVect on splicing (ElSharawy et al. 2006; Hull et al. 2007;
Nembaware et al. 2008) and a number of tools exist forHum Genet (2009) 126:481–498 491
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identiWcation of splicing-related genomic elements (Carte-
gni et al. 2003; Thierry-Mieg and Thierry-Mieg 2006).
There are multiple accounts of splicing SNPs with an
impact in cancer risk, with many of these being identiWed in
the breast-cancer susceptibility gene BRCA1 (Mazoyer
et al. 1998; Pettigrew et al. 2005). Splicing mutations and
polymorphisms can aVect phenotype in several ways.
ModiWcation of a splicing donor or acceptor site could aVect
splicing eYciency, which can result in unwanted constitu-
tive splicing or reduced splicing. Altering splicing enhanc-
ers or silencers could have a similar aVect of aVecting
splicing eYciency. Alternative splicing is a well-known
phenomenon that could also be aVected by genetic varia-
tion. The large amount of transcript data available now sug-
gests that alternative splicing is an extremely prevalent
process in human, and misregulation of this process could
produce undesirable phenotypes (Blencowe 2006). Several
splicing-related mutations have been identiWed in cis-acting
sequences that aVect cancer-related genes and drive cancer
formation. Li-Fraumeni syndrome and Peutz–Jeghers syn-
drome are hereditary genetic disorders that substantially
increase risk and both have been linked to splicing-related
polymorphisms (Hastings et al. 2005; Warneford et al.
1992).
In a non-cancer example related to post-transcriptional
regulation, Uitte de Willige et al. (2007) found that a single
SNP in the alternatively spliced Wbrinogen gamma (FGG)
gene leads to increased risk for deep-venous thrombosis.
Linkage studies found that a particular haplotype of FGG
was associated with increased disease risk and reduced pro-
tein levels. The C10034T SNP was discovered to be pri-
marily responsible for this phenotype, and sequence
evidence suggested that this SNP could be disrupting the
normal polyadenylation signal and in fact increasing poly-
adenylation of one isoform relative to another and disrupt-
ing the ratios of protein production. This phenomenon is
similar to rSNP variations resulting in misregulated gene
expression except that it occurs at the post-transcriptional
level, demonstrating that disruption of proper protein pro-
duction at any stage could lead to deleterious eVects.
In another example, where disruption of post-transcrip-
tional gene expression regulation results in disease risk,
there have been numerous studies linking mutations in the
Hmga2 gene to cancer risk (Fedele et al. 2001; Lee and
Dutta 2007; Mayr et al. 2007). Many of these mutations are
a result of a truncation in the open-reading frame (ORF) of
the Hmga2 gene, but a subset of these do not disrupt the
ORF but instead only truncate the 3 untranslated region
(UTR). The Hmga2 3 UTR contains several conserved
binding sites for the let-7 miRNA and experimental evi-
dence suggests that let-7 is involved in post-transcriptional
repression of Hmga2 production. Further studies conWrmed
that, indeed, truncation of the Hmga2 3 UTR was responsi-
ble for loss of let-7 repression, which in turn leads to onco-
genesis (Lee and Dutta 2007; Mayr et al. 2007). In a
manner similar to Hmga2/let-7, there is evidence that
miRNA SNPs can also be involved in altering drug
response. For example, the C829T SNP in the 3 UTR of
dihydrofolate reductase appears to aVect miRNA-depen-
dent regulation of DHFR expression. DHFR is the target of
the commonly used chemotherapeutic agent methotrexate
and studies have shown that SNP C829T causes loss of
miR24 miRNA binding and results in DHFR overexpres-
sion which in turn drives resistance to methotrexate
(Mishra et al. 2007).
There are many tools available for predicting the poten-
tial functional impact of SNPs, whether they aVect the cod-
ing sequence of a protein, the sequences regulating the
expression of a gene, or other aspects of protein expression.
In addition, there are several databases available that cata-
log known SNPs and provide tools for selecting SNPs
under speciWed criteria. A number of resources have been
developed speciWcally to assist in analysis of potential reg-
ulatory SNPs (Table 3). For instance, rSNP_Guide (Pon-
omarenko et al. 2002,  2003) and SNP@Promoter (Kim
et al. 2008) both store known SNPs, but speciWcally attempt
to associate them with known transcription factor-binding
sites for identiWcation of potential regulatory SNPs. MAP-
PER is a companion tool to the SNPper retrieval system
and database that locates computationally predicted tran-
scription factor-binding sites (Riva and Kohane 2002).
Both PolyMAPr (Freimuth et al. 2005) and PupaSNP
Finder (Conde et al. 2006) use computational methods to
Wnd possible exon splicing enhancer sites that can then be
mapped to SNP locations to Wnd SNPs that potentially
aVect splicing. Other than simply attempting to map SNPs
to potential transcription factor-binding sites or promoter
regions to Wnd SNPs that may have regulatory signiWcance,
the tools will also use functional information provided by
databases, such as HGMD (Stenson et al. 2008) or OMIM
(Amberger et al. 2009) to attempt to provide a functional
annotation to some SNPs. Figure 1 shows a schematic of
the various sorts of functional mutations that are possible
and what tools are available for analysis of each type of
functional region. The greatest number of methods exists
for analysis of non-synonymous coding mutations, but
there are tools available that attempt to identify each of the
non-coding functional regions, such as exonic splicing
enhancers (Cartegni et al. 2003), splice junctions (Stamm
et al. 2006; Thierry-Mieg and Thierry-Mieg 2006), polyad-
enylation sites (Lambert et al. 2004; Tabaska and Zhang
1999) (http://www.imtech.res.in/raghava/polyapred/), tran-
scription enhancers (Hallikas et al. 2006; Palin et al. 2006),
micro-RNA-binding sites (Enright et al. 2003; GriYths-
Jones et al. 2008; Wang 2008), and transcription factor-
binding sites (Matys et al. 2003; Sandelin et al. 2004).492 Hum Genet (2009) 126:481–498
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Furthermore, a recent study has shown that some regions of
the genome have evolutionarily conserved three-dimen-
sional DNA structures that correlate with non-coding func-
tional genomic regions, thereby providing another method
for identiWcation of important substitutions (Parker et al.
2009). In each of these cases, even if there is not a tool that
speciWcally predicts the potential functional impact of a
sequence alteration, simply examining the diVerence in
scores between the wild-type and mutated sequences is a
method that can be universally applied. These algorithms
could then provide a comprehensive means of functional
prediction on all kinds of genetic variations.
Although the examples of functional non-coding SNPs
presented above are all naturally occurring polymorphisms,
it is likely that somatically gained mutations would have
similar functional eVects. The focus of most large-scale
cancer sequencing projects to date has been on Wnding
mutations in coding regions, with the majority of sequenc-
ing projects focusing on transcript sequence. Because of
this data-generation bias, the amount of sequence data
available for non-coding regions of the human genome is
substantially smaller than for coding regions, but the exten-
sive evidence from SNP data presented above implies that
it is likely that some cancers may at least be partially driven
by regulatory, splicing, or miRNA mutations. With the
release of the Wrst completely sequenced cancer genome
and other cancer sequencing projects with coverage beyond
that of just the coding regions (Ley et al. 2008), the data are
becoming available to fully explore the extent of non-cod-
ing mutations in cancer.
Conclusion
The Weld of cancer mutation research is speeding up dra-
matically as the rate of data generation increases for
advancements in sequencing technology. With the success
of targeted cancer therapeutics, it appears that there is a sig-
niWcant beneWt to be gained from continued eVorts to iden-
tify genes and mutations that drive cancer development.
The recent cancer genome sequencing projects are just the
beginning of what will likely to be a continued Xood of
mutation data as next generation sequencing technologies
continue to increase throughput and decrease cost, enabling
the examination of both more regions of the genome as well
as more samples. The combination of these factors empha-
sizes the need for robust computational pipelines for analy-
sis of mutation data. Frequency-based methods are best
equipped to leverage the statistical beneWts of large data-
sets, but they may be subject to some weaknesses that
amino acid-change-based methods can mitigate. Methods
targeted to speciWc types of proteins (such as kinases and
their targets) have also shown that they can be more eVective
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than generalized tools due to their ability to incorporate
more speciWc models and reduce noise through prior
knowledge (Radivojac et al. 2008; Torkamani and Schork
2008). Integration of other datasets, such as genome-wide
expression and copy number analysis will also be crucial in
providing the best candidates for focused analysis (TCGA
2008).
Many of the issues resulting from small sample size or a
candidate gene approach that were present in early studies
will be mitigated through the decreasing cost of sequenc-
ing. However, the rapidly approaching dream of inexpen-
sive complete genome sequencing will also bring about a
new set of analysis challenges. Current cancer genome
sequencing projects are able to constrain their analysis by
focusing on protein-coding regions and non-synonymous-
coding mutations since that is the majority of generated
data. Next generation sequencing eVorts will likely include
the copious amounts of non-coding genomic sequence pres-
ent in the human genome which have not yet been exam-
ined by most existing sequencing eVorts. The results from
GWAS and small-scale experiments have already demon-
strated that non-coding mutations can have a signiWcant
impact on cellular function, but novel analysis methods are
needed to leverage this new data.
The exponentially increasing ability to sequence has
enabled experiments that were previously prohibitively
expensive. This new technology leads to an exciting time in
the Weld of cancer mutation research, but puts the burden on
the computational tools to provide the greatest value from
the generated data. Next generation tools will have to be
both accurate and fast to process the large amounts of
incoming data, and it will require multilateral eVorts to
fully mine each dataset.
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